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Abstract
Purpose The relentless rise in antimicrobial resistance is a major societal challenge and requires, as part of its solution, a better
understanding of bacterial colonization and infection. To facilitate this, we developed a highly efficient no-wash red optical
molecular imaging agent that enables the rapid, selective, and specific visualization of Gram-positive bacteria through a bespoke
optical fiber–based delivery/imaging endoscopic device.
Methods We rationally designed a no-wash, red, Gram-positive-specific molecular imaging agent (Merocy-Van) based on
vancomycin and an environmental merocyanine dye. We demonstrated the specificity and utility of the imaging agent in
escalating in vitro and ex vivo whole human lung models (n = 3), utilizing a bespoke fiber–based delivery and imaging device,
coupled to a wide-field, two-color endomicroscopy system.
Results The imaging agent (Merocy-Van) was specific to Gram-positive bacteria and enabled no-wash imaging of S. aureus
within the alveolar space of whole ex vivo human lungs within 60 s of delivery into the field-of-view, using the novel imaging/
delivery endomicroscopy device.
Conclusion This platform enables the rapid and specific detection of Gram-positive bacteria in the human lung.
Keywords Optical imaging . Fluorescence . Bacteria . Gram-positive . Lung . Optical endomicroscopy
This article is part of the Topical Collection on Infection and
inflammation
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Introduction
Gram-positive bacteria are responsible for a vast range of se-
rious clinical pathologies, including infections of wounds, col-
onization of indwelling medical devices including catheters
and prosthetic joints, and ventilator-associated pneumonia
(VAP) [1–3]. Such infections result in significant morbidity,
mortality and healthcare costs meaning that accurate and rapid
diagnosis of these infections is critical for the initiation of
appropriate treatment [4]. Traditional diagnostic practices for
infection rely on bacterial culture, which may take several
days to yield a result or techniques such as the polymerase
chain reaction (PCR), which have a tendency to be overly
sensitive [5, 6].
Developments in optical technologies [7, 8] have opened
new avenues for point-of-care diagnosis of disease; however,
in the area of bacterial infection, success has been limited by a
lack of targeted imaging agents with the required sensitivity,
specificity, and compatibility [9, 10]. Gram-positive species
such as Staphylococcus aureus and Streptococcus spp. are
responsible for approximately one-third of all VAP in the
intensive care unit. Current diagnostic strategies for VAP rely
on the interpretation of non-specific clinical symptoms, mean-
ing that half of patients receive an incorrect diagnosis and one-
third of cases are missed [3, 11]. Thus, a VAP diagnostic
strategy could benefit from technological advances offered
by optical endomicroscopy and suitable molecular imaging
agents [12, 13].
Here we describe the rational development and characteri-
zation of a highly specific, selective, rapidly reporting fluores-
cent glycopeptide-based imaging agent that has no require-
ment for a wash or processing step, and demonstrate its utility
in detecting Gram-positive bacteria within seconds in a whole
explanted human lung. This was achieved using a novel dis-
posable endoscopic delivery/imaging device comprising two
delivery capillaries and an optical fiber imaging bundle,
allowing the imaging agent to be delivered (< 100 μg) directly
into the field-of-view within the alveolar space.
The Gram-positive optical molecular imaging agent was
rationally designed based on the clinically utilized glycopep-
tide antibiotics vancomycin and oritavancin—with the knowl-
edge that oritavancin is produced by reductive amination (with
h y d r o p h ob i c g r o u p s ) o f t h e n a t u r a l p r o d u c t
chloroeremomycin (an analogue of vancomycin). This gives
analogues with far greater activity than chloroeremomycin or
vancomycin themselves due to the duality of binding
modes—the hydrophobic anchor binding into and disrupting
the cell membrane and the classic glycopeptide inhibition of
transpeptidation, whilst retaining specificity towards Gram-
positive bacteria [14–17].
Thus, our rationale was that the incorporation of an envi-
ronmentally sensitive hydrophobic dye (merocyanine) by sim-
ilar chemistry would give highly selective imaging probes
(similar in function to oritavancin). Additionally, this chemis-
try would allow not only selective attachment at a known
single site on vancomycin, but it would also leave behind an
amino group, thus enhancing solubility and specificity. The
merocyanine core was modified with a benzaldehyde type
moiety to further mimic the chemistry of chloroeremomycin
conversion to oritavancin, which uses an arylaldehyde.
The environmentally sensitive dye utilized was based on
merocyanine, which comprises electron donor (D) and accep-
tor (A) components connected by double bonds (the so-called
D-π-A system). This makes the dye very sensitive to changes
in polarity and viscosity, while also displaying a high extinc-
tion coefficient and quantum yield; thus, it fluoresces brightly
in hydrophobic environments (including the bacterial mem-
brane) [18–21].
Merocy-Van is the first example of a red-shifted, environ-
mentally activated bacterial imaging agent, and it demon-
strates superior specificity and binding kinetics to Gram-
positive bacteria compared with previously reported targeting
agents [10, 22]. Moreover, these compounds also had “al-
ways-on” fluorophores, precluding them from topical applica-
tion and rapid bedside imaging. Furthermore, the excitation
and emission in the “red” shifts the dye away from the classi-
cal green autofluorescence of tissue, making it a promising
candidate for imaging applications.
The imaging fiber was fabricated from optical fiber pre-
forms [23] and was subsequently co-packaged with two glass
capillaries into a Pebax® outer layer and a polyimide inner
layer with a steel braid reinforcement. The distal end was
terminated with a stainless steel end cap, and a fiber optic
connector at the proximal end for connectivity to the imaging
system [24].
In this study, the topical application of Merocy-Van via the
capillary channels of our endoscopy device provided a novel
delivery approach into ex vivo human lungs and was per-
formed simultaneously with two-color endomicroscopy imag-
ing. The imaging agent delivery and two-color imaging capa-
bility enabled both structural and functional information to be
collected and exemplifies significant advances in bacterial op-
tical imaging agent design, and in optical endomicroscopy.
Results
Synthesis of a Gram-positive specific imaging agent
A benzaldehyde-modified merocyanine was synthesized in
three steps (Supporting Information Scheme S1) starting from
commercially available 2,3,3-trimethyl-3H-indolenine, which
was alkylated with 4-(chloromethyl)benzyl alcohol.
Microwave-assisted condensation [20] of the acceptor
(indolenine) with the benzothiophene donor gave the benzyl
alcohol–modified merocyanine, which was then oxidized
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(using Dess-Martin periodinane) to give the merocyanine-
aldehyde (Merocy-Ald). The imaging agent (Merocy-Van)
was generated via reductive amination chemistry [17] of
Merocy-Ald via the vancosamine side chain of vancomycin,
and purified by reverse phase HPLC (Fig. 1). It proved, as
designed, to be environmentally sensitive with an exmax and
emmax of 590 nm and 620 nm (Fig. 1d).
Merocy-Van demonstrated selectivity for Gram-
positive bacteria
Selectivity for Gram-positive bacteria was assessed
against a panel of clinically relevant Gram-positive and
Gram-negative bacteria, and freshly isolated human pe-
ripheral blood granulocytes and mononuclear cells.
Merocy-Van demonstrated rapid bacterial staining of en-
capsulated (S. pneumoniae) and non-encapsulated Gram-
posi t ive bacteria with high signal- to-noise in a
concentration-dependent manner (50% max intensity at
0.1 μM) without the need to remove unbound excess
probe or requiring a washing procedure (Fig. 2 and Fig.
S1). Importantly, Merocy-Van was also able to label
MRSA within biofilms of depths of > 10 μM (Fig. S2).
Merocy-Van labelling of Gram-positive bacteria was fully
orthogonal to the green Gram-negative imaging agent
NBD-PMX (PMX (polymyxin)) [13] (Fig. 2c).
Merocy-Van retained Gram-positive toxicity but was
non-cytotoxic
The probe, as expected for oritavancin, caused complete growth
inhibition of S. aureus and S. pneumoniae at 1 μM while the
growth rate of Escherichia coli remained unaffected (Fig. S3).
Merocy-Van was non-toxic and non-hemolytic to eukaryotic
cells (Fig. S4), an important pre-requisite for clinical translation.
Fiber development and performance
The three-in-one device was fabricated using an imaging fiber
(8100 cores with an imaging square diagonal of 450 μm and a
center-to-center core separation of 3.5 μm) and two fluid de-
livery channels formed from a fused silica glass tube drawn
down to a 410-μm capillary (inner diameter of 326 μm). The
imaging fiber was fabricated from optical fiber preforms pro-
duced for the telecommunications industry (Draka/Prysmian
OM1multi-mode preform) and showed improved performance
Fig. 1 Synthesis and characterization of the environmentally responsive
imaging agent. a Synthesis of Merocy-Van by reductive amination of
vancomycin with the aldehyde dye. bHPLC trace of the purified imaging
agent (detection at 600 nm). c HRMS spectra of Merocy-Van
(experimental trace (top) vs theoretical (bottom)). d Absorbance (dashed
trace) and emission spectra of the imaging agent with increasing levels of
DMSO (DMSO/saline, vol/vol)
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in terms of imaging contrast with no compromise in resolution
over conventional imaging fibers formed from significantly
more expensive starting glasses [23]. Both the imaging fiber
and the capillary fibers were coated, as they were drawn, with a
UV curable acrylate polymer to protect the outer surfaces from
damage. Biocompatible tubing (Pebax® outer layer and a pol-
yimide inner layer with a steel braid reinforcement) was used to
co-package the three individual fibers (2 × capillaries, 1 × im-
aging fiber), and the three fibers were fixed in place at the distal
end inside a 5-mm long stainless steel end cap with an epoxy
(Epotek 301). An epoxy fiber splitter was formed at the prox-
imal end (Epotek 301). After the splitter, the three fibers were
individually sheathed in the Pebax® tubing; the two fluid chan-
nels were terminated with Luer lock fittings and the imaging
fiber was terminated with a large bore fiber optic connector
(Fig. 3). The delivery system is intended to deliver small bo-
luses to alveolar regions of less than 0.5 cm3 for point imaging/
sampling. This was achieved, with the fluid channels able to
readily deliver 0.5 mL of fluid from a 2-mL syringe in under
20 s in a continuous flow.
Fig. 2 Merocy-Van selectively labels Gram-positive bacteria. a
S. aureus , MRSA, S. epidermidis , S. pneumoniae , E. coli ,
P. aeruginosa, and S. aureus/mononuclear cell (PBMC) or granulocyte
(PMN) co-cultures were imaged by confocal microscopy following the
addition of 5 μM probe (magenta). Image inserts show counterstained
bacteria/cells (green). Representative images from nine fields-of-view
from three independent repeats. Scale bar = 5 μm. b Quantification of
images from (a) (relative fluorescence intensity from n = 90 bacteria, n =
20 mononuclear cell, and n = 20 granulocyte per condition, one-way
ANOVA ****P < 0.0001). Dashed line shows background fluorescence.
c Wash-free confocal imaging of Gram-negative (green) and Gram-
positive (magenta) bacteria with NBD-PMX and Merocy-Van. Primary
isolated human mononuclear cells were pre-labeled with Hoechst prior to
adding to the confocal chamber. Scale bar = 5 μm, n = 3
Eur J Nucl Med Mol Imaging
Delivery of Merocy-Van enabled rapid visualization of
Gram-positive bacterial in an ex vivo human lung
model
Merocy-Van and the optical fiber–based endoscope were
evaluated using an explanted ventilated human lung model.
S. aureus was instilled into the right lower lobe (a common
area of the lung for VAP to occur [25]), and Pseudomonas
aeruginosa was instilled into anatomically distinct lobes as a
negative control (Fig. 3e and f). The bacterial inoculum
instilled correlated to a bronchoalveolar lavage (BAL) retriev-
al of ~ 104 colony forming units (CFU) mL−1, in line with
clinical thresholds for pneumonia diagnosis [12, 26]. Optical
endomicroscopy imaging was performed with a wide-field
imaging system [24] with appropriate LED and filter sets for
the excitation/detection of tissue autofluorescence (green (488
nm, 500–550 nm)) and activated Merocy-Van (red (590
nm, 615–675 nm)) (Fig. 3a). Imaging was simultaneously
captured in the two-color channels, with 500 μL of Merocy-
Van (1 μM) delivered down the glass capillaries of the optical
fiber–based endoscope into the imaging field-of-view. Videos
were captured throughout the Merocy-Van instillation process
to enable real-time, in situ visualization of probe activation.
In all three individual ex vivo lung experiments, a clear
increase red fluorescence was observed for S. aureus lung
segments following dosing of Merocy-Van (average 20-fold
increase within 60 s compared with control lobes) (Fig. 3g and
h, and Fig. S5 and S6, and Supporting InformationMovies S1,
Fig. 3 Merocy-Van selectively labels S. aureus in an ex vivo human lung
model. a The endomicroscopy fluorescence imaging system used. b The
packaged three-in-one fiber-based endomicroscopy device. c End of view
of the distal tip of the fiber-based endomicroscopy device. The outer
diameter of the device is 1.4 mm, and the optical imaging bundle field-
of-view is 450 μm (right of the image) and the internal diameter of the
glass capillaries is 326 μm. d Image of the imaging fiber (8100 cores). e
Diagram of a human lung and infection/imaging locations used. f Image
of an ex vivo human lung undergoing ventilation with the imaging device
inserted within the distal lung (blue light within the white circle). Insert
shows blow-up of device distal end location (blue light). gRepresentative
images of real-time Merocy-Van (1 μM) delivery into human ex vivo
lung (baseline and following 0.4 nmol delivery shown) within S. aureus
(top) and control (bottom) lung lobes. Green: capturing lung autofluores-
cence. Red: capturing activated Merocy-Van. Each large panel shows
two-color overlay; insert shows red channel only. Scale bar = 50 μm. h
Average red fluorescence intensity per frame during real-time delivery of
0.4 nmol Merocy-Van (1 μM) into S. aureus and control lung lobes (data
shown from lung 1, see Fig. S5 for lungs 2 and 3)
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S2, S3). The relative intensity collected from the green chan-
nel remained constant throughout. Following the imaging pro-
cedure, a BAL was performed and the retrieved sample plated
for CFU determination. S. aureus was only retrieved from the
S. aureus lobes, and for each of the three lungs, 104–
105 CFU mL−1 was recovered.
Discussion
We have demonstrated the rational design of a red-shifted,
environmental, highly selective optical molecular imaging
agent to enable real-time detection of Gram-positive bacteria
using a dual-color molecular alveoscopy approach. The probe
Merocy-Van displayed Gram-positive specificity, no detect-
able cytotoxicity, and was able to generate high signal-to-
noise within seconds of administration into the human distal
lung with clinically relevant levels of Gram-positive bacteria.
Merocy-Van was dosed directly into the imaging field-of-
view without requiring a wash-step, enabling both structural
(alveolar location) and functional (Gram-positive bacteria) in-
formation to be discerned in real time. Merocy-Van showed
superior specificity and binding kinetics to Gram-positive bac-
teria compared with any other previously reported agents [10,
22]. The choice of fluorophore was critical—many
fluorophores carry a surfeit of negative charge or are always
“on”—which can inhibit the binding ligand from interacting
with fidelity to its target, or generate a high background signal
[10]. Our approach to the development of Merocy-Van dem-
onstrates a significant advancement in this area and means that
the probe could be utilized in a range of other diagnostic
applications.
We evaluated Merocy-Van in a human lung model. The
three-in-one optical fiber–based endoscope allows for optical
imaging to be proximal to chemical probe delivery as well as
providing a capillary for sample removal. Our approach
showed it was sensitive and robust, with the alveoscopy pro-
cedure performed by three independent clinicians within this
study, and offers advantages over conventional lavage pro-
cessing because the detection and results are presented direct-
ly in real time at the site of infection.
Whilst the lung is a large organ and it is not feasible to
sample each lobe or sub-section with our fiber-based tech-
nique, the clinician can be guided to the bronchopulmonary
region of interest based on x-ray or CT scans for fiber-based
interrogation and probe delivery, or select the posterior seg-
ment of the right lower lobe if changes were widespread, as
has previously been demonstrated [13]. The initial clinical
application is intended for the bedside evaluation of respirato-
ry deterioration and new pulmonary infiltrates in intubated
and ventilated patients in critical care. In these patients, with
suspected VAP which has a high morbidity and mortality,
antibiotic stewardship is important, yet often broad spectrum
antibiotics are prescribed without microbial confirmation of
distal lung infection. The intended clinical utility is to provide
a high negative predictive value to excluding distal alveolar
infection due to Gram-positive bacteria with a threshold to
delineate low-grade colonization from de novo infection.
The imaging will be performed in a standardized manner,
and the technology now requires clinical validation in pro-
spective studies to determine performance and health econom-
ic benefit as an adjunct to existing care pathways.
Beyond these initial clinical indications, our approach also
allows access to the distal lung with targeted sampling of
discrete regions; this has the potential to aid in microbiome
research as traditional processing of lavage or tracheal aspi-
rates are not necessarily indicative of the area of interest due to
cross-contamination [27, 28]; however, these applications are
beyond the scope of this study.
Conclusion
In conclusion, we have presented a strategy for the in situ
detection of Gram-positive bacteria in a whole human
ex vivo ventilated lung, paving the way for simultaneous,
multiplexed, multicolor imaging in vivo in real time.
Combining optical molecular imaging agents and our three-
in-one optical fiber–based endoscope constructs could aid
point-of-care diagnostic decisions and provide a platform to
interrogate dynamic biological processes in situ.
Methods
Chemistry and biology reagents and methods Chemistry and
biology reagents and methods are described in detail in the
Supporting Information.
Ethical approval All experiments using human samples were
performed following approval of the appropriate regional
ethics committee (REC), NHS Lothian, and the South East
Scotland Research Ethics Committee 02 (references 15/HV/
013 and 11/SS/0103), and with informed consent.
Experiments were conducted within three explanted human
lungs (Fig. 3 and Fig. S5 and S6, and Supporting
Information Movies S1, S2, S3).
Optical imaging agent characterization All imaging agents
were solubilized in 0.9% NaCl (used at concentrations of
1 μM or 5 μM). Absorbance and emission spectra were de-
termined on a microplate reader (BioTek Synergy H1 multi-
mode reader). Data were collected in duplicate from three
independent repeats.
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Human explanted lung model Human lungs were obtained
from solid organ donors after being declined by all UK
transplant centers as being unsuitable for transplantation.
They were flushed in situ and retrieved as per standard
clinical practice for organ retrieval and transported on ice.
Lungs were split and single lung ventilation (Drager
Savina 300) performed using PEEP 5, tidal volume of
3.5 mL kg−1 and a respiratory rate of 12. Following re-
cruitment of the lungs, the bronchoscope was wedged
proximally in each lobe, and 2 mL of 108 CFU mL−1
S. aureus was instilled into the lower lobe, and 2 mL of
108 CFU mL−1 P. aeruginosa or 2 mL 0.9% NaCl were
instilled into the upper or middle lobes as negative con-
trols via a flexible catheter (1.5-mm-diameter APC cathe-
ter, Erbe). Following a 60-min incubation, the endoscopic
device was passed down the working channel of a bron-
choscope to the lobe where saline or bacteria had been
instilled, and into the alveolar space. This was confirmed
by imaging in the green channel. Five hundred microliters
of 1 μM Merocy-Van was instilled into the lung through
the capillaries of the endoscopic device within the field-
of-view, in 5 × 100 μL (5 × 0.1 nmol) installments. Dual-
color videos were captured throughout each instillation of
Merocy-Van. Images were captured as previously de-
scribed [24] with 50-ms exposure and a frame rate of 8
frames per second. The endoscopic device (including in-
ternally within the delivery capillaries) was cleaned with
8% H2O2 between imaging each lobe. Following all im-
aging, each lobe underwent BAL with 20 mL 0.9% NaCl
(Baxter), with a retrieval rate of 40–50%. BAL samples
were serially diluted and plated for CFU counting to con-
firm bacterial presence from each lobe. The study was
completed using lungs from three individual donors.
Human explanted lung model image analysis Bespoke image
analysis tools were developed in-house. To extract fluores-
cence intensity levels, MATLAB scripts were written that
detect and mark the area of the fiber facet as the region of
interest (ROI) of an image. The script subsequently removes
the background signal (acquired in a calibration step during
every experiment) and, in a second step, computes the mean
fluorescence intensity levels of the ROI of every image of a
given set. Off target frames were removed from analysis.
For display purposes, the image processing we implement-
ed was a method similar to one previously reported [29]. Our
implementation first subtracts fiber bundle autofluorescence,
then removes high spatial frequency noise from the image,
and then corrects for fiber core transmission heterogeneity
through normalization. Each video file was brightness- and
contrast-enhanced (maintaining the same settings per experi-
ment) and exported to create real-time imaging videos.
Individual representative images from each video file were
saved as TIFs.
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